340B Drug Pricing Program
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
The AHA today submitted
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to…
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to…
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to…
The full U.S. Court of Appeals for the District of Columbia Circuit denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.
The full U.S. Court of Appeals for the District of Columbia Circuit Oct. 16 denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.
AHA urges HHS to stop drug companies’ refusal to provide required 340B discounts
AHA follows up on our previous correspondence on the serious situation Eli Lilly, AstraZeneca and Sanofi are creating for the nation’s most vulnerable communities by refusing to comply with the requirements of the 340B program to sell to contract pharmacies at the discounts required by section 340B…